Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 21, 2015 5:03 PM ET

Company Overview of Federal Trade Commission

Company Overview

600 Pennsylvania Avenue

NW

Washington, DC 20580

United States

Phone:

202-326-2222

Key Executives for Federal Trade Commission

Chief of Staff
Chair of Covington's Antitrust and Consumer Law Practice Group
Chief Privacy Officer
Chief Technologist
Acting Chief Information Officer
Compensation as of Fiscal Year 2014.

Federal Trade Commission Key Developments

Cardinal Health to Pay $26.8 Million in Federal Trade Commission Settlement

Cardinal Health will pay $26.8 million as part of a settlement with the Federal Trade Commission over charges it monopolized the sale in 25 markets of diagnostic drugs known as low-energy radiopharmaceuticals. The charges allege that the company forced hospitals and clinics to pay inflated prices for the drugs, used to diagnose a range of conditions, including heart disease. The Federal Trade Commission said that Cardinal Health did this by employing various tactics to get both Bristol Myers-Squibb and General Electric Co. to refuse to grant distribution rights for their radiopharmaceuticals used in heart stress tests to potential Cardinal competitors in those 25 markets. Without rights for those agents, competitors' businesses were not financially viable. The settlement money will be placed in a fund that will be distributed to customers who had to pay the inflated prices.

Federal Trade Commission Approves Final Order Preserving Competition in Market for Braf- and Mek-Inhibitor Oncology Drugs

Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Novartis AG's $16 billion acquisition of GlaxoSmithKline's portfolio of cancer-treatment drugs likely would be anticompetitive. Under the order, first announced in February 2015, Novartis has agreed to divest all assets related to its BRAF- and MEK-inhibitor drugs, currently in development, to Boulder, Colorado-based Array BioPharma. The Commission vote approving the final order was 5-0.

Federal Trade Commission Obtains Settlement from Network Solutions LLC for Misleading Consumers About Refunds

Network Solutions LLC has agreed to settle Federal Trade Commission charges that it misled consumers who bought its web hosting services by promising a full refund if they canceled within 30 days. In reality, the company withheld substantial cancellation fees from most refunds. In an administrative complaint, the FTC alleged that Network Solutions, a domain name registrar and web hosting provider, offered web hosting packages with a '30 Day Money Back Guarantee,' but did not adequately disclose that it withheld part of the refund - up to 30% - from customers who cancelled within 30 days of buying an annual or multi-year package and registering an included domain name. The proposed settlement order prohibits Network Solutions from failing to clearly disclose, before obtaining a customer's billing information, the material terms of any money-back guarantee, or failing to refund the full purchase price in response to a request that complies with the terms of a guarantee. The settlement also bars the company from misrepresenting material terms of any refund or cancellation policy or money-back guarantee, or any other material fact about web hosting. The FTC acknowledges the assistance of the Better Business Bureau serving Metro Washington DC and Eastern Pennsylvania in this case. The Commission vote to issue an administrative complaint and accept the proposed consent agreement for public comment was 5-0. The FTC will publish a description of the consent agreement package in the Federal Register shortly. The agreement will be subject to public comment for 30 days, beginning April 7, 2015 and continuing through May 7, 2015, after which the Commission will decide whether to issue the order on a final basis.

Similar Private Companies By Industry

Company Name Region
LifeStar EMS United States
Power Facilities Investors LP United States
Sekisui Specialty Chemicals America Llc United States
Stewart Title of Bellingham, Inc. United States
SWB Enterprises, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Federal Trade Commission, please visit www.ftc.gov. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.